Patents by Inventor Edgar Jacoby
Edgar Jacoby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230091047Abstract: The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. The disclosure further pertains to methods for preparing compounds according to Formula (I).Type: ApplicationFiled: March 13, 2020Publication date: March 23, 2023Inventors: Sandrine Céline GROSSE, Jan Martin BERKE, Meng-yang HSIAO, Lili HU, Edgar JACOBY, Tim Hugo Maria JONCKERS, Bart Rudolf Romanie KESTELEYN, Stefaan Julien LAST, Carlolina MARTINEZ LAMENCA, Mathieu PERRIER, Serge Maria Aloysius PIETERS, Pierre Jean-Marie Bernard RABOISSON, Abdellah TAHRI, Koen VANDYCK, Wim Gaston VERSCHUEREN
-
Patent number: 11491148Abstract: The application relates to amide derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection:Type: GrantFiled: May 5, 2020Date of Patent: November 8, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Bart Rudolf Romanie Kesteleyn, Jan Martin Berke, Erwin Coesemans, Sandrine Céline Grosse, Edgar Jacoby, Tim Hugo Maria Jonckers, Stefaan Julien Last, Wim Gaston Verschueren, Michel Obringer, Christelle Catherine Cecile Doebelin
-
Publication number: 20220259186Abstract: The disclosure describes pyridinone-containing inhibitors of PD-L1, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds, and their use in the treatment of infectious diseases and cancer.Type: ApplicationFiled: June 5, 2020Publication date: August 18, 2022Inventors: David Craig MC GOWAN, Edgar JACOBY
-
Publication number: 20220089568Abstract: Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.Type: ApplicationFiled: January 10, 2020Publication date: March 24, 2022Inventors: Justin Cisar, Scott Kuduk, Chao-yuan Wang, Yvan Rene Ferdinand Simonnet, Colleen Elizabeth Keohane, Edgar Jacoby
-
Patent number: 11236084Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: July 4, 2018Date of Patent: February 1, 2022Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Calum Macleod, Samuel Edward Mann, Janusz Jozef Kulagowski, Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel
-
Patent number: 11186589Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: February 6, 2020Date of Patent: November 30, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 11180487Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: January 20, 2017Date of Patent: November 23, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
-
Patent number: 11136311Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: June 29, 2017Date of Patent: October 5, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 11096931Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.Type: GrantFiled: February 21, 2020Date of Patent: August 24, 2021Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Stefaan Julien Last, Bart Rudolf Romanie Kesteleyn, Sandrine Céline Grosse, Tim Hugo Maria Jonckers, Jan Martin Berke, Geerwin Yvonne Paul Haché, Edgar Jacoby, Carolina Martinez Lamenca, Morgan Charles R. Lecomte, Abdellah Tahri, Sarah Sauviller, Karen Maria Vergauwen
-
Patent number: 11053248Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.Type: GrantFiled: October 31, 2017Date of Patent: July 6, 2021Assignee: Janssen Pharmaceutica NVInventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
-
Publication number: 20210188840Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoinmmune disorders.Type: ApplicationFiled: July 4, 2018Publication date: June 24, 2021Inventors: George HYND, Calum MACLEOD, Samuel Edward MANN, Janusz Jozef KULAGOWSKI, Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL
-
Patent number: 11001569Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: January 20, 2017Date of Patent: May 11, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
-
Publication number: 20210087182Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: January 20, 2017Publication date: March 25, 2021Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
-
Patent number: 10947242Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.Type: GrantFiled: October 31, 2017Date of Patent: March 16, 2021Assignee: Janssen Pharmaceutica, NVInventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Gary John Tresadern, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Edgar Jacoby, Gregor James Macdonald, Henricus Jacobus Maria Gijsen, Abdellah Ahnaou, Wilhelmus Helena Ignatius Maria Drinkenburg
-
Publication number: 20210032267Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: February 6, 2020Publication date: February 4, 2021Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Publication number: 20200352925Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.Type: ApplicationFiled: May 5, 2020Publication date: November 12, 2020Inventors: Bart Rudolf Romanie KESTELEYN, Jan Martin BERKE, Erwin COESEMANS, Sandrine Céline GROSSE, Edgar JACOBY, Tim Hugo Maria JONCKERS, Stefaan Julien LAST, Wim Gaston VERSCHUEREN, Michel OBRINGER, Christelle Catherine Cecile DOEBELIN
-
Publication number: 20200268730Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.Type: ApplicationFiled: February 21, 2020Publication date: August 27, 2020Inventors: Stefaan Julien LAST, Bart Rudolf Romanie KESTELEYN, Sandrine Céline GROSSE, Tim Hugo Maria JONCKERS, Jan Martin BERKE, Geerwin Yvonne Paul HACHÉ, Edgar JACOBY, Carolina MARTINEZ LAMENCA, Morgan Charles R. LECOMTE, Abdellah TAHRI
-
Publication number: 20200109129Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or disorders.Type: ApplicationFiled: January 20, 2017Publication date: April 9, 2020Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Gerhard Mx GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
-
Publication number: 20200048260Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.Type: ApplicationFiled: October 31, 2017Publication date: February 13, 2020Applicant: Janssen Pharmaceutica NVInventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
-
Publication number: 20190359598Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: June 29, 2017Publication date: November 28, 2019Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann